Screening and adenocarcinoma of the cervix

International Journal of Cancer

Volumn 125, Issue 3, 2009, Pages 525-529

  Sasieni, Peter ^a   Castanon, Alejandra ^a   Cuzick, Jack ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Efficacy; Screening

Indexed keywords

ADENOSQUAMOUS CARCINOMA; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; DATA BASE; DIAGNOSTIC ACCURACY; DISEASE DURATION; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROGNOSIS; RISK REDUCTION; SQUAMOUS CELL CARCINOMA; UNITED KINGDOM; UTERINE CERVIX ADENOCARCINOMA; UTERINE CERVIX ADENOSQUAMOUS CARCINOMA; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CYTOLOGY; VAGINA SMEAR;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; COLPOSCOPY; FEMALE; GREAT BRITAIN; HUMANS; INCIDENCE; LOGISTIC MODELS; MASS SCREENING; MIDDLE AGED; NEOPLASM INVASIVENESS; UTERINE CERVICAL NEOPLASMS;

EID: 67650083308     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24410     Document Type: Article

References (29)

1. IARC Working Group on Cervical Cancer Screening. Screening for squamous cervical cancer - the duration of low risk following negative results in cervical cytology test: introduction. IARC Sci Publ 1986:15-24.
2. Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Parkin DM. International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. Int J Cancer 1998;75:536-45.
3. Sasieni P, Adams J. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet 2001;357: 1490-3.
4. Nieminen P, Kallio M, Hakama M. The effect of mass screening on incidence and mortality of squamous and adenocarcinoma of cervix uteri. Obstet Gynecol 1995;85:1017-21.
5. Mitchell H, Medley G, Gordon I, Giles G. Cervical cytology reported as negative and risk of adenocarcinoma of the cervix: no strong evidence of benefit. Br J Cancer 1995;71:894-7.
6. Crocetti E, Battisti L, Betta A, Palma PD, Paci E, Piffer S, Pojer A, Polla E, Zappa M. The cytological screening turned out effective also for adenocarcinoma: a population-based case-control study in Trento, Italy. Eur J Cancer Prev 2007;16:564-7.
7. Zappa M, Visioli CB, Ciatto S, Iossa A, Paci E, Sasieni P. Lower protection of cytological screening for adenocarcinomas and shorter protection for younger women: the results of a case-control study in Florence. Br J Cancer 2004;90:1784-6.
8. Andrae B, Kemetli L, Sparen P, Silfverdal L, Strander B, Ryd W, Dillner J, Tornberg S. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst 2008;100:622-9.
9. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer 2007;120:885-91.
10. Sasieni P, Adams J, Cuzick J. Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer 2003;89:88-93.
11. Sasieni PD, Cuzick J, Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. Br J Cancer 1996;73:1001-5.
12. Herbert A, Singh N, Smith JA. Adenocarcinoma of the uterine cervix compared with squamous cell carcinoma: a 12-year study in Southampton and South-west Hampshire. Cytopathology. 2001;12: 26-36.
13. National Patient Safety Agency. Defining research. National Research Ethics Service, vol.2008. London: National Patient Safety Agency, 2008.
14. Breslow NE, Day NE. Statistical methods in cancer research. Volume I-the analysis of case-control studies. IARC Sci Publ 1980;32:5-338.
15. Sobin L, Wittekind CH. TNM classification of malignant tumours, 6th edn. Geneva, Switzerland: UICC Internation Union against Cancer, 2002. 155-7.
16. Kosary CL. Cancer of the cervix uteri. In: Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-JD. SEER survival monograph: cancer survival among adults: U.S. SEER Program, 1988-2001. Patient and tumor characteristics. Bethesda, MD: National Cancer Institute, SEER Program, NIH Pub No. 07-6215, 2007.
17. Zheng T, Holford TR, Ma Z, Chen Y, Liu W, Ward BA, Boyle P. The continuing increase in adenocarcinoma of the uterine cervix: a birth cohort phenomenon. Int J Epidemiol 1996;25:252-8.
18. Schoolland M, Segal A, Allpress S, Miranda A, Frost FA, Sterrett GF. Adenocarcinoma in situ of the cervix. Cancer 2002;96:330-7.
19. Krane JF, Granter SR, Trask CE, Hogan CL, Lee KR. Papanicolaou smear sensitivity for the detection of adenocarcinoma of the cervix: a study of 49 cases. Cancer 2001;93:8-15.
20. Boon ME, Ouwerkerk-Noordam E, van Leeuwen AW, Kok LP, van Haaften-Day C. How to improve cytologic screening for endocervical adenocarcinoma? Eur J Gynaecol Oncol 2002;23:481-5.
21. Castellsague X, Diaz M, de Sanjose S, Munoz N, Herrero R, Franceschi S, Peeling RW, Ashley R, Smith JS, Snijders PJ, Meijer CJ, Bosch FX. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006;98:303-15.
22. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Munoz N. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008;26 (Suppl 10):K1-16.
23. Boon ME, Baak JP, Kurver PJ, Overdiep SH, Verdonk GW. Adenocarcinoma in situ of the cervix: an underdiagnosed lesion. Cancer 1981;48:768-73.
24. Health and Social Care Information Centre, Cervical Screening Programme, England: 2005-2006. NHS Health and Social Care Information Centre, Community Health Statistics, 2006.
25. Bergstrom R, Sparen P, Adami HO. Trends in cancer of the cervix uteri in Sweden following cytological screening. Br J Cancer 1999;81:159-66.
26. Gunnell AS, Ylitalo N, Sandin S, Sparen P, Adami HO, Ripatti S. A Longitudinal Swedish Study on screening for squamous cell carcinoma and adenocarcinoma: evidence of effectiveness and overtreatment. Cancer Epidemiol Biomarkers Prev 2007;16:2641-48.
27. van de Nieuwenhof HP, Massuger LF, de Hullu JA, van Ham MA, van Dijck JA, Siebers AG, Bekkers RL. Significant decrease of adenocarcinoma in situ not reflected in cervical adenocarcinoma incidence in the Netherlands 1989-2003. Br J Cancer 2008;98:165-7.
28. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97:1072-9.
29. Pak SC, Martens M, Bekkers R, Crandon AJ, Land R, Nicklin JL, Perrin LC, Obermair A. Pap smear screening history of women with squamous cell carcinoma and adenocarcinoma of the cervix. Aust N Z J Obstet Gynaecol 2007;47:504-7.